Global Anal Cancer Therapeutics Market 2018 by Manufacturers, Countries, Type and Application, Forecast to 2024

Published On: April 2019 | Report ID: 157347 | Category: Pharmaceuticals and HealthcarePages: 115

A cancer can be defined when the normal cells lose their ability to control, their growth or multiplication and thus invade the tissues and spread to the body parts. Anal cancer is often called as squamous cell carcinoma which arises from the cells around or in the anal opening or in rare cases it may cause in the anal canal. This type of cancer is usually associated with human papiloma virus (HPV), where HPV cancers or cervical cancers have a high risk of developing into anal cancer. There are no exact symptoms for anal cancer as such but some might show bleeding from the anal area, lump or swelling near anus or change in the bowel habits etc.  Staging is a way which describes the location of cancer, the stages include tumor, node and metastasis which is further grouped I, II, IIIA, IIIB and IV. The different types of anal cancer include melanoma, adenocarcinoma, basaloid transitional and cloacogenic cancer.

Scope of the Report:

This report studies the Anal Cancer Therapeutics market status and outlook of Global and major regions, from angles of players, countries, product types and end industries; this report analyzes the top players in global market, and splits the Anal Cancer Therapeutics market by product type and applications/end industries.

The statistics for anal cancer suggest that annually there about 6000 cases of anal cancer diagnosed in the U.S. and the number is increasing slowly. The major factors that drive the market for anal cancer therapeutics are aging population, sexually transmitted disease, multiple sexual partners and smoking. According to the World Health Organization 290 million women are suffering from HPV infection and due to unhealthy sex, the chances get doubled. For treating this anal cancer, early diagnosis is crucial which is only available in the developed countries or high-income countries and are accessible. Whereas in the low-income countries the diagnosis and treatment facilities are either costly or inaccessible. These factors are responsible for holding back the anal cancer therapeutics market and should be well tracked for future advancements.

The global Anal Cancer Therapeutics market is valued at xx million USD in 2017 and is expected to reach xx million USD by the end of 2023, growing at a CAGR of xx% between 2017 and 2023.

The Asia-Pacific will occupy for more market share in following years, especially in China, also fast growing India and Southeast Asia regions.

North America, especially The United States, will still play an important role which cannot be ignored. Any changes from United States might affect the development trend of Anal Cancer Therapeutics.

Europe also play important roles in global market, with market size of xx million USD in 2017 and will be xx million USD in 2023, with a CAGR of xx%.

Market Segment by Companies, this report covers

GlaxoSmithKline Pharmaceuticals

Spectrum Pharmaceuticals

Hospira

Global BioPharma

Advaxis

Market Segment by Regions, regional analysis covers

North America (United States, Canada and Mexico)

Europe (Germany, France, UK, Russia and Italy)

Asia-Pacific (China, Japan, Korea, India and Southeast Asia)

South America (Brazil, Argentina, Colombia)

Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)

Market Segment by Type, covers

Fluorouracil

Cisplatin

Carboplatin

Market Segment by Applications, can be divided into

Hospitals

Long-Term Care Centers

Pharmacies

Diagnostic Laboratories

Table of Contents

1 Anal Cancer Therapeutics Market Overview

1.1 Product Overview and Scope of Anal Cancer Therapeutics

1.2 Classification of Anal Cancer Therapeutics by Types

1.2.1 Global Anal Cancer Therapeutics Revenue Comparison by Types (2017-2023)

1.2.2 Global Anal Cancer Therapeutics Revenue Market Share by Types in 2017

1.2.3 Fluorouracil

1.2.4 Cisplatin

1.2.5 Carboplatin

1.3 Global Anal Cancer Therapeutics Market by Application

1.3.1 Global Anal Cancer Therapeutics Market Size and Market Share Comparison by Applications (2013-2023)

1.3.2 Hospitals

1.3.3 Long-Term Care Centers

1.3.4 Pharmacies

1.3.5 Diagnostic Laboratories

1.4 Global Anal Cancer Therapeutics Market by Regions

1.4.1 Global Anal Cancer Therapeutics Market Size (Million USD) Comparison by Regions (2013-2023)

1.4.1 North America (USA, Canada and Mexico) Anal Cancer Therapeutics Status and Prospect (2013-2023)

1.4.2 Europe (Germany, France, UK, Russia and Italy) Anal Cancer Therapeutics Status and Prospect (2013-2023)

1.4.3 Asia-Pacific (China, Japan, Korea, India and Southeast Asia) Anal Cancer Therapeutics Status and Prospect (2013-2023)

1.4.4 South America (Brazil, Argentina, Colombia) Anal Cancer Therapeutics Status and Prospect (2013-2023)

1.4.5 Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa) Anal Cancer Therapeutics Status and Prospect (2013-2023)

1.5 Global Market Size of Anal Cancer Therapeutics (2013-2023)

2 Manufacturers Profiles

2.1 GlaxoSmithKline Pharmaceuticals

2.1.1 Business Overview

2.1.2 Anal Cancer Therapeutics Type and Applications

2.1.2.1 Product A

2.1.2.2 Product B

2.1.3 GlaxoSmithKline Pharmaceuticals Anal Cancer Therapeutics Revenue, Gross Margin and Market Share (2016-2017)

2.2 Spectrum Pharmaceuticals

2.2.1 Business Overview

2.2.2 Anal Cancer Therapeutics Type and Applications

2.2.2.1 Product A

2.2.2.2 Product B

2.2.3 Spectrum Pharmaceuticals Anal Cancer Therapeutics Revenue, Gross Margin and Market Share (2016-2017)

2.3 Hospira

2.3.1 Business Overview

2.3.2 Anal Cancer Therapeutics Type and Applications

2.3.2.1 Product A

2.3.2.2 Product B

2.3.3 Hospira Anal Cancer Therapeutics Revenue, Gross Margin and Market Share (2016-2017)

2.4 Global BioPharma

2.4.1 Business Overview

2.4.2 Anal Cancer Therapeutics Type and Applications

2.4.2.1 Product A

2.4.2.2 Product B

2.4.3 Global BioPharma Anal Cancer Therapeutics Revenue, Gross Margin and Market Share (2016-2017)

2.5 Advaxis

2.5.1 Business Overview

2.5.2 Anal Cancer Therapeutics Type and Applications

2.5.2.1 Product A

2.5.2.2 Product B

2.5.3 Advaxis Anal Cancer Therapeutics Revenue, Gross Margin and Market Share (2016-2017)

3 Global Anal Cancer Therapeutics Market Competition, by Players

3.1 Global Anal Cancer Therapeutics Revenue and Share by Players (2013-2018)

3.2 Market Concentration Rate

3.2.1 Top 5 Anal Cancer Therapeutics Players Market Share

3.2.2 Top 10 Anal Cancer Therapeutics Players Market Share

3.3 Market Competition Trend

4 Global Anal Cancer Therapeutics Market Size by Regions

4.1 Global Anal Cancer Therapeutics Revenue and Market Share by Regions

4.2 North America Anal Cancer Therapeutics Revenue and Growth Rate (2013-2018)

4.3 Europe Anal Cancer Therapeutics Revenue and Growth Rate (2013-2018)

4.4 Asia-Pacific Anal Cancer Therapeutics Revenue and Growth Rate (2013-2018)

4.5 South America Anal Cancer Therapeutics Revenue and Growth Rate (2013-2018)

4.6 Middle East and Africa Anal Cancer Therapeutics Revenue and Growth Rate (2013-2018)

5 North America Anal Cancer Therapeutics Revenue by Countries

5.1 North America Anal Cancer Therapeutics Revenue by Countries (2013-2018)

5.2 USA Anal Cancer Therapeutics Revenue and Growth Rate (2013-2018)

5.3 Canada Anal Cancer Therapeutics Revenue and Growth Rate (2013-2018)

5.4 Mexico Anal Cancer Therapeutics Revenue and Growth Rate (2013-2018)

6 Europe Anal Cancer Therapeutics Revenue by Countries

6.1 Europe Anal Cancer Therapeutics Revenue by Countries (2013-2018)

6.2 Germany Anal Cancer Therapeutics Revenue and Growth Rate (2013-2018)

6.3 UK Anal Cancer Therapeutics Revenue and Growth Rate (2013-2018)

6.4 France Anal Cancer Therapeutics Revenue and Growth Rate (2013-2018)

6.5 Russia Anal Cancer Therapeutics Revenue and Growth Rate (2013-2018)

6.6 Italy Anal Cancer Therapeutics Revenue and Growth Rate (2013-2018)

7 Asia-Pacific Anal Cancer Therapeutics Revenue by Countries

7.1 Asia-Pacific Anal Cancer Therapeutics Revenue by Countries (2013-2018)

7.2 China Anal Cancer Therapeutics Revenue and Growth Rate (2013-2018)

7.3 Japan Anal Cancer Therapeutics Revenue and Growth Rate (2013-2018)

7.4 Korea Anal Cancer Therapeutics Revenue and Growth Rate (2013-2018)

7.5 India Anal Cancer Therapeutics Revenue and Growth Rate (2013-2018)

7.6 Southeast Asia Anal Cancer Therapeutics Revenue and Growth Rate (2013-2018)

8 South America Anal Cancer Therapeutics Revenue by Countries

8.1 South America Anal Cancer Therapeutics Revenue by Countries (2013-2018)

8.2 Brazil Anal Cancer Therapeutics Revenue and Growth Rate (2013-2018)

8.3 Argentina Anal Cancer Therapeutics Revenue and Growth Rate (2013-2018)

8.4 Colombia Anal Cancer Therapeutics Revenue and Growth Rate (2013-2018)

9 Middle East and Africa Revenue Anal Cancer Therapeutics by Countries

9.1 Middle East and Africa Anal Cancer Therapeutics Revenue by Countries (2013-2018)

9.2 Saudi Arabia Anal Cancer Therapeutics Revenue and Growth Rate (2013-2018)

9.3 UAE Anal Cancer Therapeutics Revenue and Growth Rate (2013-2018)

9.4 Egypt Anal Cancer Therapeutics Revenue and Growth Rate (2013-2018)

9.5 Nigeria Anal Cancer Therapeutics Revenue and Growth Rate (2013-2018)

9.6 South Africa Anal Cancer Therapeutics Revenue and Growth Rate (2013-2018)

10 Global Anal Cancer Therapeutics Market Segment by Type

10.1 Global Anal Cancer Therapeutics Revenue and Market Share by Type (2013-2018)

10.2 Global Anal Cancer Therapeutics Market Forecast by Type (2018-2023)

10.3 Fluorouracil Revenue Growth Rate (2013-2023)

10.4 Cisplatin Revenue Growth Rate (2013-2023)

10.5 Carboplatin Revenue Growth Rate (2013-2023)

11 Global Anal Cancer Therapeutics Market Segment by Application

11.1 Global Anal Cancer Therapeutics Revenue Market Share by Application (2013-2018)

11.2 Anal Cancer Therapeutics Market Forecast by Application (2018-2023)

11.3 Hospitals Revenue Growth (2013-2018)

11.4 Long-Term Care Centers Revenue Growth (2013-2018)

11.5 Pharmacies Revenue Growth (2013-2018)

11.6 Diagnostic Laboratories Revenue Growth (2013-2018)

12 Global Anal Cancer Therapeutics Market Size Forecast (2018-2023)

12.1 Global Anal Cancer Therapeutics Market Size Forecast (2018-2023)

12.2 Global Anal Cancer Therapeutics Market Forecast by Regions (2018-2023)

12.3 North America Anal Cancer Therapeutics Revenue Market Forecast (2018-2023)

12.4 Europe Anal Cancer Therapeutics Revenue Market Forecast (2018-2023)

12.5 Asia-Pacific Anal Cancer Therapeutics Revenue Market Forecast (2018-2023)

12.6 South America Anal Cancer Therapeutics Revenue Market Forecast (2018-2023)

12.7 Middle East and Africa Anal Cancer Therapeutics Revenue Market Forecast (2018-2023)

13 Research Findings and Conclusion

14 Appendix

14.1 Methodology

14.2 Data Source

Please fill the form below, to recieve the report sample

Name*
Email*
Phone*
Name of the Company*
Title / Designation*
Country*
Your specific requirements*
Human Verification*

Please fill the form below for enquiry

Name*
Email*
Phone*
Name of the Company*
Title / Designation*
Country*
Your specific requirements*
Human Verification*
Choose License Type



Why Choose Us

  24/7 Research support

Get your queries resolved from an industry expert. Request for a free product review before report purchase.

Email: sales@mrinsights.biz

  Custom research service

Speak to the report author to design an exclusive study to serve your research needs.

  Information security

Your personal and confidential information is safe and secure.